Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | COSMOS: key updates for MOR208 plus venetoclax for R/R CLL

Jennifer Woyach • 6 Dec 2018
ASH 2018
Chronic Lymphocytic Leukemia Leukemia Tafasitamab Venetoclax
COSMOS

Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Jennifer Woyach, MD, of the Ohio State University College of Medicine, Columbus, OH, discusses the results of the COSMOS trial (NCT02639910), investigating anti-CD19 MOR208 in combination with venetoclax in chronic lymphocytic leukemia (CLL) patients who discontinued BTK inhibitor therapy. This revealed encouraging activity, with acceptable safety and tolerability.

More from Jennifer Woyach

1:04
6-year follow-up of ELEVATE-TN: sustained safety and efficacy in CLL
Jennifer Woyach • 8 Dec 2023
1:18
Pirtobrutinib in patients with CLL/SLL previously exposed to covalent BTKi: insights from BRUIN
Jennifer Woyach • 8 Dec 2023
2:57
LP-168: a novel next-generation BTK inhibitor with dual activity in CLL
Jennifer Woyach • 8 Dec 2023
0:49
BRUIN CLL-322: pirtobrutinib plus VR vs VR alone in R/R CLL
Jennifer Woyach • 7 Oct 2023

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals